Soleus Capital Management’s Revolution Medicines RVMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.44M Buy
+36,249
New +$7.19M 0.26% 63
2025
Q3
– Sell
-10,000
Closed -$368K – 103
2025
Q2
$368K Sell
10,000
-74,784
-88% -$2.87M 0.02% 91
2025
Q1
$3M Sell
84,784
-116,300
-58% -$4.72M 0.22% 57
2024
Q4
$8.8M Sell
201,084
-503,500
-71% -$25.4M 0.55% 43
2024
Q3
$32M Sell
704,584
-151,594
-18% -$6.6M 2.47% 13
2024
Q2
$33.2M Buy
856,178
+127,478
+17% +$4.76M 2.93% 7
2024
Q1
$23.5M Buy
728,700
+476,700
+189% +$14.1M 1.74% 15
2023
Q4
$7.23M Buy
+252,000
New +$6.06M 0.8% 39
2021
Q3
– Sell
-125,700
Closed -$3.99M – 82
2021
Q2
$3.99M Buy
125,700
+68,500
+120% +$2.39M 0.61% 34
2021
Q1
$2.62M Buy
+57,200
New +$2.57M 0.47% 43

Other funds holding RVMD

Soleus Capital Management's RVMD Position: Q3 2026 in Review

Soleus Capital Management opened a new position in Revolution Medicines (RVMD) in Q3 2026: 36,249 shares worth $7.44M. The stake represents 0.26% of the portfolio and ranks #63 among its holdings. This is a return to the name: Soleus Capital Management previously reported a position in RVMD as recently as Q2 2025.

Soleus Capital Management first reported a position in RVMD in Q1 2021 and has held it in 10 quarters since. The position peaked at $33.2M in Q2 2024. 760 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • Soleus Capital Management held 36,249 shares of Revolution Medicines worth $7.44M as of Q3 2026.
  • Revolution Medicines was a new Soleus Capital Management position in Q3 2026.
  • Revolution Medicines made up 0.26% of Soleus Capital Management's portfolio in Q3 2026, its #63 holding.
  • Soleus Capital Management first reported a position in Revolution Medicines in Q1 2021 and has held it in 10 quarters since.
  • Soleus Capital Management's Revolution Medicines position peaked at $33.2M in Q2 2024.
  • 760 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Soleus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.